Thanks for you opinion and comments, balance is good on a board. My comments;
They have not shown a profit yet because they are transitioning from R&D to product sales.
I never heard anything regarding your comments about their marketing savvy.
Yes dilution sucks. I believe it is already priced in.
You may be right about the press releases, although they have not had a significantly impacting one in a while.
Hopefully most on this board sold when the pps was high. I have been open with my moves and only hold a small position right now. I am waiting to see what happens.
They are on the way to making a profit.
They did have a product returned by one retailer, but it on amounted to a $1.4 mil loss.
Some DD from the filings:
Anticipates revenues of approx $42.2 million for 2007, an increase of almost 300% compared to 2006
Sales of the Branded Products Group were $13.6 million for the three month period ended March 31, 2007 compared to $34 thousand for the same period a year ago
Anticipate a net loss for 2007 of $18.2 million. This includes a one-time net charge of $1.4 million in the fourth quarter for the return of Selenomax®.
The net loss for the year reflects the investments made by the Company to transition from a research and development-focused company selling chromium picolinate as an ingredient, to a sales and marketing-driven company selling branded consumer products
Preparing for the Fall 2007 launches of Advanced Memory FormulaTM and Diabetes Essentials®, a line of nutritional supplements for people with type-2 diabetes. Major retailers and key regional retailers have already placed purchase orders for both products.
The chromium category grew by 37.1% in the drug channel, and Chromax® became the #1 selling chromium brand at retail
Chromium picolinate was incorporated as an ingredient into Ross/Abbott’s Glucerna, the leading diabetes nutrition shake, Coca-Cola, Minute Maid Multi and, in the past month, a newly launched Diet Coke
Iceland Health direct response sales grew 15% on an annualized basis since its acquisition in August 2006
Nutrition 21 expects revenue for fiscal year 2008 to be in the range of approximately $70 to $80 million, a 66% to 94% increase over our preliminary estimates for fiscal 2007 revenue
News 
Market Data 
Discover 
